Skip to main content
  1. Right Decisions
  2. Scottish Palliative Care Guidelines
  3. Back
  4. Medicines information
  5. Methadone
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Methadone

Red – For medicines normally initiated and used under specialist guidance

Introduction

The information below is intended as a guide for use in primary and secondary care to support the management of patients receiving methadone as a third-line analgesic for complex pain. 

Methadone should only be started by a consultant in palliative medicine and patients require ongoing specialist supervision.  

 

Description

Methadone is a potent, synthetic opioid. Methadone has complex pharmacokinetics and a long half-life. There is a risk of accumulation, especially in elderly patients.

Preparations

Tables are best viewed in landscape mode on mobile devices

Oral

Methadone tablets

Methadone liquid

5mg (preferred form)

1mg/ml (green)

10mg/ml (blue)

Injection

Methadone injection

10mg/ml (1ml, 2ml, 3.5ml, 5ml ampoules)

 

Indications

Methadone is only used as a third-line opioid for patients with complex pain that is poorly responsive to other opioids, or where these opioids have resulted in intolerable side effects.

  • Patient has responded poorly or had intolerable side effects from first and second-line opioids (for example morphine, diamorphine, oxycodone, fentanyl).
  • In complex neuropathic pain: if the patient has not responded to first and second-line opioid and adjuvant analgesic combinations.
  • In end-stage chronic kidney disease (eGFR less than 30ml/min).

Adjuvant methadone may also be used for the above indications under specialist supervision.

 

Cautions

Methadone should always be used with caution but particularly in the following situations.

  • Methadone has a long and unpredictable half-life which can lead to side effects/severe opioid toxicity without a change in the regular dose, particularly when methadone is started for the first time – careful monitoring is needed.
  • Patients with incident pain or unstable pain where repeated doses of methadone may accumulate and cause opioid toxicity.
  • Pain suspected to have a strong psychological component as repeated demands for as needed doses of methadone may lead to opioid toxicity.

 

Drug interactions:

  • Hepatic methadone metabolism varies considerably between individuals and this variability is responsible for the large differences in methadone clearance and the doses needed to manage pain. 
  • QTMethadone levels may increase if given with fluoxetine, sertraline, clarithromycin, ciprofloxacin, fluconazole. Methadone should not be given with monoamine oxidase inhibitors (for example phenelzine and linezolid) or within 2 weeks of stopping them.
  • Methadone levels may decrease if given with phenytoin, phenobarbital, carbamazepine, St John’s Wort.
  • Concurrent administration with medications that affect methadone metabolism via the hepatic cytochrome P450 system (CYP3A4) – refer to British National Formulary (BNF). Methadone can cause QT prolongation – caution with other drugs that may have this effect, for example QTclarithromycin, amitriptyline, QTcitalopram, QTdomperidone, prochlorperazine, QThaloperidol, QTamiodarone. Refer to BNF.

 

Liver impairment: Reduced clearance. Dose reduction may be necessary.

Renal impairment: No dose reduction necessary. Not significantly removed by dialysis.

 

Side effects

  • Patient may become unexpectedly drowsy or develop respiratory depression particularly when first starting methadone – refer to cautions above.
  • Side effects that are common to all opioids, including dry mouth, constipation may be less common.

 

Dose and administration

  • Patients starting methadone will usually require inpatient admission for 5 to 7 days. A stable methadone dose for 48 to 72 hours before discharge is needed.  
  • Methadone may occasionally be started safely as an adjuvant analgesic for selected patients in the community. The palliative care specialist will recommend an individual dosing regimen and discuss and review the management plan with the patient’s GP.
  • Methadone is usually given twice daily (occasionally three times daily). 
  • A shorter acting opioid than methadone is often used for breakthrough pain in patients on a stable methadone dose. 
  • The methadone dose and the timing of doses should not be changed without instructions from a palliative medicine specialist.

 

Discontinuing methadone: Seek specialist advice.

This may be needed if treatment is ineffective, the patient is experiencing side effects, is unable to take oral medication or is in the last days of life.

 

Practice points

  • Undertake an individual risk assessment prior to initiating methadone. Consider if drug diversion/misuse is likely and if weekly/twice weekly dispensing from a community pharmacy is required.
  • Discuss the methadone prescription with the GP and provide written information.
  • Ensure the GP is aware which methadone preparation should be prescribed if the patient is receiving methadone liquid.
  • Ensure the patient is reviewed by a member of the specialist palliative care team as soon as possible after discharge (within 2 to 3 days).
  • Discuss the prescription with community pharmacy and explain methadone has been prescribed for pain management not drug dependency.

 

References

Blackburn D. Methadone: the analgesic. European Journal of Palliative Care 2005;12:188-191.

Nicholson AB. Methadone for cancer pain. Cochrane database of systematic reviews 2008;(4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003971.pub3/pdf/standard

Prommer EE. Methadone for cancer pain. Palliative Care: Research & treatment 2010; 4(1-10).

Twycross R et al. Palliative Care Formulary (4th Ed). Palliativedrugs.com Ltd, Nottingham, 2011.

Acknowledgement: Brown DJF. Methadone for cancer pain: A reference for specialists. St Columba’s Hospice, Edinburgh, 2007.